Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 409

A groundbreaking way of measuring fluid buildup in the body allows chronic heart failure patients to monitor their condition and treat it independently with a physician-approved response.

Tel Aviv-based startup Vectorious has created a tiny pressure sensor that is implanted directly into the heart. It is the only sensor in the world that measures the pressure in the left atrium (one of the heart’s two upper chambers) and is able to identify increases in that pressure caused by a buildup of fluid in the body.

This data on the left atrial pressure (LAP) is then transmitted to an app for the patient and their doctor.

Read more | >

Our willingness to help others is governed by a specific brain region pinpointed by researchers in a study of patients with brain damage to that region.

Learning about where in the brain “helping” decisions are made is important for understanding how people might be motivated to tackle large global challenges, such as climate change, infectious disease and international conflict. It is also essential for finding new approaches to treating disorders of social interactions.

The study, published in Nature Human Behaviour, was carried out by researchers at the University of Birmingham and the University of Oxford, and shows for the first time how a region called the ventromedial prefrontal cortex (vmPFC) has a critical role in helping, or “prosocial” behaviors.

Read more | >

In the future, getting help for depression might involve a quick brain scan to find the most effective treatment for you.

An analysis of brain activity during rest and while undertaking specific tasks among a large group of people with depression and anxiety has identified six distinct types of brain activity patterns, symptoms, and responses to treatment.

The team from the US and Australia who conducted the study also determined treatments that are more likely to work for some of these categories. This means doctors could potentially match patients with the best therapies based on how their brains function.

Read more | >

Over the past decade, immune checkpoint inhibitors (ICI) have revolutionized the cancer treatment area. These drugs block the interaction between proteins known as immune checkpoints and immune cells within our bodies. At times, immune checkpoints play a vital role in immune regulation, preventing unnecessary responses. However, tumors can upregulate proteins, thus evading an immune response, and in a tumor setting, this response is indeed necessary. ICIs interfere with checkpoint pathways and allow active immunity against cancer.

In 2011, the United States Foor and Drug Administration (FDA) approved the first ICI, ipilimumab, a CTLA-4 blocker, for treating advanced melanoma. Subsequently, ICIs targeting PD1 (pembrolizumab and nivolumab) and PDL1 (atezolizumab and durvalumab) received approval for treating various malignancies. Many clinical trials test the efficacy of novel ICIs in different settings.

A recent study published in Science Immunology unveiled a promising new avenue for cancer immunotherapy and ICIs. The study evaluated a drug targeting an immune checkpoint molecule called VISTA (V-domain immunoglobulin suppressor of T cell activation), shedding light on its potential as an effective immunotherapy target.

Read more | >